Skip to main navigation Skip to search Skip to main content

Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays

  • David M. Hyams
  • , Eric Schuur
  • , Javier Angel Aristizabal
  • , Juan Enrique Bargallo Rocha
  • , Cesar Cabello
  • , Roberto Elizalde
  • , Laura García-Estévez
  • , Henry L. Gomez
  • , Artur Katz
  • , Aníbal Nuñez De Pierro
  • Eisenhower Medical Center
  • VMWA LLC
  • National Institute of Cancer
  • National Cancer Institute
  • University of Campinas
  • Hospital Dr. Ignacio Pirovano
  • Centro Integral Oncológico Comprensivo Clara Campal
  • Instituto Nacional de Enfermedades Neoplásicas Eduardo Cáceres Graziani
  • Center of Check of Hospital Sirio Libanes
  • Hospital General de Agudos Juan A Fernández

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations

Abstract

Risk stratification of patients with early stage breast cancer may support adjuvant chemotherapy decision-making. This review details the development and validation of six multi-gene classifiers, each of which claims to provide useful prognostic and possibly predictive information for early stage breast cancer patients. A careful assessment is presented of each test's analytical validity, clinical validity, and clinical utility, as well as the quality of evidence supporting its use.

Original languageEnglish
Pages (from-to)647-662
Number of pages16
JournalJournal of Surgical Oncology
Volume115
Issue number6
DOIs
StatePublished - 1 May 2017
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • adjuvant
  • biomarkers
  • breast neoplasms
  • chemotherapy
  • clinical decision-making
  • gene expression
  • genomics risk
  • prognosis
  • tumor

Fingerprint

Dive into the research topics of 'Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays'. Together they form a unique fingerprint.

Cite this